Cover Image

Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenström’s macroglobulinemia: results of a retrospective analysis of the Société Française de Greffe de Moelle et de Thérapie Cellulaire

Background Patients with poor-risk Waldenström’s macroglobulinemia have suboptimal response and early post-treatment relapse with conventional therapies. Hence, new therapeutic approaches such as allogeneic stem cell transplantation should be evaluated in these patients.Design and Methods We examin...

Full description

Saved in:
Bibliographic Details
Main Authors: Garnier, Alice (Author) , Robin, Marie (Author) , Larosa, Fabrice (Author) , Golmard, Jean-Louis (Author) , Gouill, Steven Le (Author) , Coiteux, Valérie (Author) , Tabrizi, Reza (Author) , Bulabois, Claude-Eric (Author) , Cacheux, Victoria (Author) , Kuentz, Mathieu (Author) , Dreyfus, Brigitte (Author) , Dreger, Peter (Author) , Rio, Bernard (Author) , Moles-Moreau, Marie-Pierre (Author) , Bilger, Karin (Author) , Bay, Jacques-Olivier (Author) , Leblond, Véronique (Author) , Blaise, Didier (Author) , Tournilhac, Olivier (Author) , Dhédin, Nathalie (Author)
Format: Article (Journal)
Language:English
Published: June, 2010
In: Haematologica, the hematology journal
Year: 2010, Volume: 95, Issue: 6, Pages: 950-955
ISSN:1592-8721
DOI:10.3324/haematol.2009.017814
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.3324/haematol.2009.017814
Verlag, kostenfrei, Volltext: https://haematologica.org/article/view/5632
Get full text
Author Notes:Alice Garnier, Marie Robin, Fabrice Larosa, Jean-Louis Golmard, Steven Le Gouill, Valérie Coiteux, Reza Tabrizi, Claude-Eric Bulabois, Victoria Cacheux, Mathieu Kuentz, Brigitte Dreyfus, Peter Dreger, Bernard Rio, Marie-Pierre Moles-Moreau, Karin Bilger, Jacques-Olivier Bay, Véronique Leblond, Didier Blaise, Olivier Tournilhac, and Nathalie Dhédin
Description
Summary:Background Patients with poor-risk Waldenström’s macroglobulinemia have suboptimal response and early post-treatment relapse with conventional therapies. Hence, new therapeutic approaches such as allogeneic stem cell transplantation should be evaluated in these patients.Design and Methods We examined the long-term outcome of allogeneic stem cell transplantation in Waldenström’s macroglobulinemia by studying the records of 24 patients reported in the SFGM-TC database and one transplanted in the bone marrow unit in Hamburg.Results Median age at the time of transplant was 48 years (range, 24-64). The patients had previously received a median of 3 lines of therapy (range, 1-6) and 44% of them had refractory disease at time of transplant. Allogeneic stem cell transplantation after myeloablative (n=12) or reduced-intensity (n=13) conditioning yielded an overall response rate of 92% and immunofixation-negative complete remission in 50% of evaluable patients. With a median follow-up of 64 months among survivors (range, 11-149 months), 5-year overall survival and progression-free survival rates were respectively, 67% (95% CI: 46-81) and 58% (95% CI: 38-75). The 5-year estimated risk of progression was 25% (95% CI: 10-36%), with only one relapse among the 12 patients who entered complete remission, versus 5 in the 12 patients who did not. Only one of the 6 relapses occurred more than three years post-transplant.Conclusions Allogeneic stem cell transplantation yields a high rate of complete remissions and is potentially curative in poor-risk Waldenström’s macroglobulinemia.
Item Description:Gesehen am 10.10.2023
Physical Description:Online Resource
ISSN:1592-8721
DOI:10.3324/haematol.2009.017814

Similar Items